Идёт набор NCT05710861

Cost-utility of Focal HIFU vs Prostatectomy

Без фазы С лечением Prostate Cancer

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают: В протоколе указаны: F-HIFU, Radical Prostatectomy.
Кому может быть актуально: Состояния в реестре: Prostate Cancer. Базовые параметры: 50 лет — 75 лет · Мужчины.
Что важно проверить: Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится: Франция, Guadeloupe
Следующий шаг: Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

Randomized Medical-Economic Trial Comparing Focal HIFU Treatment to Total Prostatectomy in Patients With Intermediate Prognosis Prostate Cancer

Обзор

Medico-Economic Randomized Trial comparing Focal HIFU Treatment to Radical Prostatectomy in Patients with Favorable Intermediate Risk Prostate Cancer

Подробное описание

Standard treatment option of intermediate risk (ISUP2) prostate cancer (PC) is either radical prostatectomy (RP) or radiation therapy (RT). An attractive option for selected patients and for the health care system would be to spare the preserved gland to decrease urinary, sexual and digestive side effects of whole-gland treatments keeping with a good cancer control. For these reasons, focal treatments have been developed in localized PC. The principal objective of the EMERHIT study is to estimate, from the health system point of view, the efficiency (cost/utility study) of focal HIFU (F-HIFU) for intermediate risk PC compared to RP (either by open, laparoscopic or robotic surgical approach) at 24 months. It will be a multicentric pragmatic clinical trial, comparative, with no insu, randomized in two parallel groups :

* (1) F-HIFU treatment * (2) RP Randomization will be equal (ratio 1:1), stratified on the centers and performed maximum at 2 months before the procedure. The comparison to the SNDS data will use the NIR of the patients selected for the study. The use of the SNDS data will allow, on top of the estimation of the care cost, to increase the patient's follow-up (with no supplemental visit) and measure, at 48 months, costs, mortality rate and cancer control measures From version 4.0 of the protocol, randomisation will be adjusted to a 2:1 ratio and stratified by centre.

Вмешательства

Устройство F-HIFU
A F-HIFU treatment will be performed with the Focal-One® machine according to the predefined treatment area for each patient using the standard procedure in place in each therapeutic center and according to the user's manual edited by the company, under locoregional or general anaesthesia.
Процедура Radical Prostatectomy
A Radical Prostatectomy will be performed according to the standard procedure in place in each center, under general anaesthesia, through an open, laparoscopic or robot-assisted laparoscopic approach

Первичные конечные точки

The cost/utility ratio expressed as differential cost per QALY in favor of F-HIFU compared to RP (open, lap or robot) at 24 months. [Срок оценки: 24 months]

Вторичные конечные точки (12)

The per-year of preserved life differential cost between F-HIFU and RP [Срок оценки: 48 months]
Differential cost between F-HIFU and open, lap or robotic RP [Срок оценки: 24 months]
Real production cost (€) of F-HIFU and RP [Срок оценки: 48 months]
Net benefit (€) for the Health Insurance [Срок оценки: 48 months]
Survival with no salvage treatmente. [Срок оценки: 12, 24 and 48 months]
Overall survival [Срок оценки: 12, 24 and 48 months]
Cancer specific survival [Срок оценки: 12, 24 and 48 months]
Androgen deprivation-free survival [Срок оценки: 12, 24 and 48 months]
Urinary and sexual functions [Срок оценки: Inclusion and 1, 6, 12 and 24 months]
Patient's quality of life [Срок оценки: Inclusion and 1, 6, 12 and 24 months]
Urinary and sexual functions [Срок оценки: Inclusion and 1, 6, 12 and 24 months]
Urinary and sexual functions [Срок оценки: Inclusion and 1, 6, 12 and 24 months]

Критерии участия

Критерии включения

45-75 yo male harboring a non-treated localized prostatic adenocarcinoma of maximum Gleason score 3+4, ISUP 2 unilateral on at most maximum 2 contiguous sextants (favorable intermediate risk),with or without ipsilateral or contralateral focus of score 3+3 (ISUP1).
Tumor visible on MRI and proven by systematic and/or targeted biopsies according to the center's practices, regardless of the route used (transrectal or transpirenal)
Or patients under active surveillance whose follow-up prostate biopsies reveal unilateral ISUP2 on at most 2 contiguous sextants (favorable intermediate risk), with or without ipsilateral or contralateral Gleason 3+3 focus (ISUP1)
Patients with several suspicious foci on MRI may be be included if only one of these foci is confirmed by targeted biopsies with an ISUP2 score. If more than one suspected site on MRI is confirmed by targeted biopsies, these should be unilateral ISUP2 on a maximum of 2 contiguous sextants (favourable intermediate risk), with or without an ipsilateral or contralateral site with a Gleason score of 3+3 (ISUP1).
stage T1c-T2,
with PSA <20 ng/ml,
with prostate volume less than 150 ml,
patient clearly informed of the study and having agreed, with sufficient time for reflection to participate by signing the study's informed consent form,
patient affiliated to or benefiting from a social security scheme

Критерии исключения

Metastatic prostate cancer.
Gleason score > 3+4 (ISUP>2).
Adenoma prostate carcinoma Cribriform or intraductal.
Previous treatment anterior for the same cancer, whatever modality.
Contra-indication to pelvic MRI with gadolinium injection.
Contra-indication to surgery or general anesthesia.
Patient who refuse the one-year follow-up control biopsy after F-HIFU.
Presence of implant (stent, catheter) less than 1 cm from the treatment area.
Urinary or rectal fistula.
Anal or rectal stenosis or any other abnormality that may interfere with the Focal One® endorectal probe introduction.
Anatomic abnormality of the rectum or rectal mucosa.
Presence of a urinary artificial sphincter, a penile prosthesis or intraprostatic implant, i.e. urethral prosthesis.
Bladder neck and/or urethral stenosis or sclerosis.
Inflammatory bowel disease (colon or rectum).
Ongoing UTI (should be treated before the F-HIFU or the RP).
Previous anal or rectal surgery that may interfere with the anal probe introduction.
Latex allergy.
Rectal wall thickness > 10 mm.
Tumor not accessible to a F-HIFU treatment (tumors located in the fibro-muscular anterior zone).
Previous not controlled cancer and/or treated since less than 5 years (except basocellular skin cancer).
Patient not able to understand the trial objectives or refusing to adhere to the trial instructions.
Patients under law-protection.
Patient in an ongoing research trial.
Patient with a severe health or psychologic problem that could impair the protocol pathway.